NasdaqGS:KRYS
NasdaqGS:KRYSBiotechs

Krystal Biotech (KRYS) Is Down 11.7% After Reporting Substantially Higher Net Income – Has The Bull Case Changed?

Earlier this week, Krystal Biotech reported quarterly and half-year earnings results, posting net income of US$38.33 million for the second quarter and US$74.07 million for the first half of 2025, both up substantially from the prior year. This marked improvement in both net income and earnings per share signals significant operational progress and momentum compared to last year. We’ll examine how these sharply higher earnings underscore Krystal Biotech’s evolving investment narrative and...
NasdaqGS:MDGL
NasdaqGS:MDGLBiotechs

Why Madrigal Pharmaceuticals (MDGL) Is Up 14.4% After Rezdiffra Patent Extension and Narrower Q2 Loss

Madrigal Pharmaceuticals recently reported its second quarter 2025 results, showing a much narrower net loss of US$42.28 million, down from US$151.97 million a year ago, alongside significant commercial progress for its lead product, Rezdiffra. The company also secured a new U.S. patent for Rezdiffra, extending exclusivity until February 2045, while advancing international expansion and pipeline development to further strengthen its market position. Let's examine how the newly extended...